Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

Clinical trial NCT00090090 · COMPLETED

Trial details

NCT number: NCT00090090
Sponsor: Spectrum Pharmaceuticals, Inc
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Mantle Cell Lymphoma Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Start date: 2004-04-01
Enrollment: 114

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.